Retatrutide

• Retatrutide is a GLP-1/GIP/GCGR agonist currently in development.
• According to clinical studies, it may help with weight loss and the regulation of blood sugar levels.
• Its mechanism of action appears to be partly similar to well-known medicines such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), but retatrutide acts on three receptors at the same time.
• The medication is still in the research phase and has not yet been approved for use in Europe.

Retatrutide targets three receptors (GLP-1, GIP, and GCGR) involved in appetite, metabolism, and blood sugar regulation. Research suggests this may lead to weight loss and improved glucose levels. As the medication is still under development, the precise effects, dosages, and long-term outcomes have not yet been established.

In clinical studies, side effects similar to those seen with other GLP-1 medications have been reported, including:

• Nausea 
• Diarrhoea 
• Fatigue

As Retatrutide is still in development, a comprehensive overview of all possible side effects is not yet available. As soon as more information emerges, this will be updated here.

Retatrutide is currently in phase 3 of clinical development. Several large-scale studies are ongoing worldwide, including the so-called TRIUMPH trials by manufacturer Eli Lilly. These studies are focusing on the effect of Retatrutide in people with obesity, type 2 diabetes, and other conditions. Further information can be found on the official trial page of Eli Lilly.

Preliminary results from a phase 2 study, published in the New England Journal of Medicine, show promising effects:

• Average weight loss of up to 24% after 48 weeks of treatment.
• Improvements in blood sugar levels and other cardiometabolic risk factors.
• The most common side effects were mild and similar to those of other GLP-1-like medicines (such as nausea and diarrhoea).

These studies are ongoing. As soon as more definitive results are available, we will update this page.

• Retatrutide has not yet been approved in Europe.
• There is currently no clarity regarding approval or availability.
• As soon as there are updates, we will publish the latest information here.

- Keep an eye on this page for the latest news about Retatrutide.

- Explore alternative weight loss treatments that are already available:

• Wegovy 
• Mounjaro

• https://pubmed.ncbi.nlm.nih.gov/38858523/  
• https://thecarepharmacy.com/retatrutide-uses-side-effects-availability-and-more/  
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10844714/